Next Article in Journal
Establishing F1A-CreERT2 Mice to Trace Fgf1 Expression in Adult Mouse Cardiomyocytes
Next Article in Special Issue
p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration
Previous Article in Journal
Selectivity of mTOR-Phosphatidic Acid Interactions Is Driven by Acyl Chain Structure and Cholesterol
Previous Article in Special Issue
Molecular Markers and Targets in Melanoma
 
 
Review

Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy—An Integrated View into Other Neoplasms and Chemokine Networks

Group of Molecular Cell Biology, Institute of Biochemistry of the Romanian Academy, 060031 Bucharest, Romania
*
Author to whom correspondence should be addressed.
These authors equally contributed to this work.
Academic Editor: Natascia Tiso
Cells 2022, 11(1), 120; https://doi.org/10.3390/cells11010120
Received: 29 October 2021 / Revised: 17 December 2021 / Accepted: 23 December 2021 / Published: 30 December 2021
Cutaneous melanoma accounts for only about 7% of skin cancers but is causing almost 90% of deaths. Melanoma cells have a distinct repertoire of mutations from other cancers, a high plasticity and degree of mimicry toward vascular phenotype, stemness markers, versatility in evading and suppress host immune control. They exert a significant influence on immune, endothelial and various stromal cells which form tumor microenvironment. The metastatic stage, the leading cause of mortality in this neoplasm, is the outcome of a complex, still poorly understood, cross-talk between tumor and other cell phenotypes. There is accumulating evidence that Interleukin-8 (IL-8) is emblematic for advanced melanomas. This work aimed to present an updated status of IL-8 in melanoma tumor cellular complexity, through a comprehensive analysis including data from other chemokines and neoplasms. The multiple processes and mechanisms surveyed here demonstrate that IL-8 operates following orchestrated programs within signaling webs in melanoma, stromal and vascular cells. Importantly, the yet unknown molecularity regulating IL-8 impact on cells of the immune system could be exploited to overturn tumor fate. The molecular and cellular targets of IL-8 should be brought into the attention of even more intense scientific exploration and valorization in the therapeutical management of melanoma. View Full-Text
Keywords: interleukin-8; chemokines; CXCL8; CXCR1; CXCR2; chemokines in tumor progression interleukin-8; chemokines; CXCL8; CXCR1; CXCR2; chemokines in tumor progression
Show Figures

Figure 1

MDPI and ACS Style

Filimon, A.; Preda, I.A.; Boloca, A.F.; Negroiu, G. Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy—An Integrated View into Other Neoplasms and Chemokine Networks. Cells 2022, 11, 120. https://doi.org/10.3390/cells11010120

AMA Style

Filimon A, Preda IA, Boloca AF, Negroiu G. Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy—An Integrated View into Other Neoplasms and Chemokine Networks. Cells. 2022; 11(1):120. https://doi.org/10.3390/cells11010120

Chicago/Turabian Style

Filimon, Anca, Iulia A. Preda, Adina F. Boloca, and Gabriela Negroiu. 2022. "Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy—An Integrated View into Other Neoplasms and Chemokine Networks" Cells 11, no. 1: 120. https://doi.org/10.3390/cells11010120

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop